Estimate the annual revenue impact of AI across two of pharma's biggest commercial gaps: patients who are never identified in time, and patients who abandon treatment before completing it.
Percentage of patients diagnosed at a late stage, based on published clinical evidence (typically 20–60%).
Net annual revenue captured per patient receiving therapy.
AI-enabled early identification can recover up to 30% of late-diagnosed patients, based on conservative implementation assumptions.
Additional patients diagnosed earlier
120,000
Incremental annual revenue opportunity
$1,800,000,000
Based on 30% reduction in late diagnosis through AI prediction models
Estimates are based on epidemiological inputs and conservative AI adoption assumptions. Results are illustrative and should be validated against local market data.
AI identifies at-risk patients before symptoms appear, expanding the treatment window. Studies show AI can predict conditions like cardiovascular disease with 90%+ accuracy years in advance (Master of Code — AI in Healthcare Statistics, 2025). AI-driven early interventions improve patient outcomes by 30-35% compared to traditional methods (Vention Teams — AI in Healthcare Statistics, 2025).
The pharma industry loses $637B annually to medication non-adherence (IQVIA Institute, 2024). 27% of all new prescriptions and 31% of specialty oncology scripts are never filled (IQVIA Oncology Access Report, 2024). AI-powered patient support programs reduce therapy discontinuation by 14-20% (Johns Hopkins School of Public Health — Pharmaceutical PAP Analysis).
Schedule a personalized demo to see how Arkangel AI can transform your pharmaceutical operations.